Stockwinners Market Radar for August 10, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:56 EDT Class action suit filed against Elon Musk, Tesla - Keller Lenkner LLC announced that a class action has been commenced on behalf of all purchasers of securities of Tesla after 12:48pm eastern standard time on August 7, 2018 through and including August 8, 2018. The action was filed in the Northern District of California and is captioned Kalman Isaacs v. Elon Musk, et al., No. 3:18-cv-04865. The complaint charges that defendant Elon Musk, the company's Chairman and CEO, and Tesla, violated the Securities Exchange Act of 1934 by issuing false and misleading statements regarding Musk taking the company private. In particular, and importantly, at 12:48pm eastern standard time on August 7, 2018, Musk issued a statement via Twitter that "funding" for the deal had been "secured." In reaction to Musk's Tweet, the price of Tesla's stock soared to an intra-day high of $387.46, $45.47 above the previous day's closing price, closing at $379.57 per share. Musk, however, was not telling the truth. Rather, he had Tweeted to decimate the company's short-sellers who were forced to cover their positions over the succeeding days at artificially inflated prices. Indeed, the price of Tesla stock also remained inflated throughout the next day, August 8, 2018. The plaintiff is represented by Keller Lenkner.

18:08 EDT Microsoft CEO sells 328,000 common shares - In a regulatory filing, Microsoft CEO Satya Nadella disclosed the sale of 328,000 common shares of the company at a price of $109.4396 per share. The value of the sold shares amounts to roughly $35.9M, according to Bloomberg.

17:18 EDT Lockheed Martin awarded $302M U.S. Navy contract - Lockheed Martin is awarded $301,980,301 for cost-plus-fixed-fee delivery order against a previously issued basic ordering agreement. This order provides for the procurement of ancillary mission equipment for F-35 Lightning II low-rate initial production Lot 12 aircraft in support of the Air Force, Marine Corps, and Navy, the non-Department of Defense participants and foreign military sales customers. Work will be performed in Fort Worth, Texas, and is expected to be completed in January 2021.

16:57 EDT Mannatech authorizes up to $500,000 share repurchase program - Mannatech announced that its board of directors has authorized the company to begin the repurchase of up to $500,000 of the company's outstanding common shares from time to time in the open market pursuant to the company's existing share repurchase program. As of July 31, 2018, the company had approximately 2.4M shares outstanding.

16:36 EDT Point adds NXP and Campbell's Soup stakes, exits Alphabet Class A - Third Point disclosed in an SEC filing its holdings as of June 30. Third Point's 13 new buys in the quarter included, by size of position, NXP Semiconductors (NXPI), PayPal (PYPL), Visa (V), Campbell Soup (CPB), and Deere (DE). The firm exited 14 positions during the quarter including, by size of previous position, Alphabet Class A (GOOGL), Intercontinental Exchange (ICE), Mohawk Industries (MHK), PagSeguro Digital (PAGS), and Anthem (ANTM). Third Point increased its stake in nine holdings, including Microsoft (MSFT), Adobe Systems (ADBE), Electronic Arts (EA), Marathon Petroleum (MPC), and United Technologies (UTX). Third Point reduced its stake in nine holdings, including Worldpay (WP), Constellation Brands Class A (STZ), Facebook (FB), Lennar (LEN), and Wynn Resorts (WYNN). The firm's top holdings as of June 30, in order of size, were Baxter (BAX), NXP Semiconductors, United Technologies, PayPal, and Netflix (NFLX).

16:35 EDT Alnylam trading resumes

16:31 EDT Newell Brands to sell Goody Products to ACON fund, terms not disclosed - Newell Brands announced that it has signed a definitive agreement to sell Goody Products, Inc., a manufacturer of hair styling tools and accessories, to a fund managed by ACON Investments, L.L.C., a private equity investment firm based in Washington, D.C. Terms were not disclosed. Goody's 2017 net sales were approximately $115M. The transaction is expected to close within approximately 30 days, subject to customary closing conditions, including regulatory approval. Baird acted as financial advisor to Newell Brands on the Goody transaction.

16:22 EDT Golden Harbor reports 12.5% stake in Inseego

16:16 EDT Badger Meter raises quarterly dividend 15% to 15c from 13c per share - The increased dividend is payable September 14 to shareholders of record on August 31.

16:07 EDT FDA approves Amicus' Galafold for treatment of patients with Fabry Disease - Amicus Therapeutics announced that the U.S. Food and Drug Administration has granted accelerated approval of Galafold (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gen variant based on in vitro assay data. Galafold was approved under the Subpart H Accelerated Approval pathway based on reduction in kidney interstitial capillary cell globotriaosylceramide substrate. As a condition of accelerated approval, Amicus Therapeutics will continue to study Galafold in a confirmatory Phase 4 program. Galafold is a capsule taken once every other day, at the same time of day. The FDA has approved Galafold for 348 amenable GLA variants. Galafold is the first oral medicine for Fabry disease, and the first new therapy approved to treat Fabry disease in the United States in more than 15 years. Fabry disease is a rare, progressive genetic disorder characterized by a defective gene that causes an enzyme deficiency. This enzyme is responsible for breaking down disease substrate that, when deficient in patients with Fabry disease, builds up in the kidneys, which is one of the organ systems impacted by Fabry disease. In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated. Globally, it is estimated that 35 to 50 percent of Fabry disease patients may have an amenable GLA variant. Amicus Therapeutics will launch Galafold immediately, and will begin shipping to a limited distribution network in the coming week.

15:58 EDT The Stars Group, Mount Airy Casino to launch online gambling in Pennsylvania - The Stars Group and Mount Airy Casino Resort announced a partnership to enter Pennsylvania's online sports wagering and gaming market. Under the partnership, The Stars Group will provide customers in Pennsylvania an all-inclusive experience by offering its popular poker, casino and sports wagering products. The Stars Group and Mount Airy Casino Resort intend to launch the offerings following applicable licensing by the Pennsylvania Gaming Control Board. The Stars Group intends to utilize its existing and proprietary technology and player account management platform for its offerings in Pennsylvania, providing customers with a single account, common wallet, various online and mobile depositing and withdrawal options, and a seamless offering of betting and gaming options. The announcement follows The Stars Group and Resorts Casino Hotel's recent extension of their existing partnership in the New Jersey regulated online gaming market to include online and mobile sports wagering through The Stars Group's BetStars brand alongside the already existing online poker and casino offering available through PokerStarsNJ and PokerStarsCasinoNJ.

15:36 EDT TherapeuticsMD up 1% to $5.25 after reopening following Annovera approval

15:29 EDT California Attorney General opposing Bayer acquisition of Monsanto - California Attorney General Xavier Becerra announced that he led a coalition of states opposing Bayer AG's (BAYRY) $66B acquisition of Monsanto (MON), which will make Bayer the largest seed company in the world. In a comment letter sent to the United States Department of Justice, the coalition of states expresses urgent concern over the concentration of the seed market. They argue that any harm to competition caused by this merger will "affect every consumer's food choices and budget." Public comment remains open for at least 60 days before the court may enter a Final Judgment on the acquisition. On May 29, the U.S. Department of Justice cleared the purchase. Reference Link

15:20 EDT Alnylam says Onpattro to be available from two specialty pharmacies

15:08 EDT TherapeuticsMD announces FDA approval of Annovera - TherapeuticsMD announced that the United States Food and Drug Administration has approved Annovera, which it said is the first long-acting prescription birth control that is patient-controlled, procedure-free and reversible. The segesterone acetate component of the Annovera contraceptive vaginal system is expected to be classified as a "new chemical entity," or NCE, by the FDA and thus will likely be entitled to five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act, TherapeuticsMD said. Annovera was developed by the global non-profit research organization, Population Council, and TherapeuticsMD said it intends to leverage the Population Council's existing relationships with the supplier of segesterone acetate and the manufacturer of the clinical trial supply of the one-year contraceptive vaginal system to scale-up commercial manufacturing of Annovera. TherapeuticsMD currently estimates that Annovera will be commercially available as early as the third quarter of 2019 with the commercial launch as early as the fourth quarter of 2019 or first quarter of 2020. The ACA mandates that private health plans provide coverage with no out-of-pocket costs for one treatment per class of in each of the classes identified by the FDA for women in its Birth Control Guide. As part of its license agreement with the Population Council, TherapeuticsMD has agreed to provide significantly reduced pricing to federally designated Title X family planning clinics serving lower-income women.

14:41 EDT Alnylam announces alignment on value-based agreements for Onpattro - Alnylam Pharmaceuticals (ALNY) announced it has agreed on the structure and key terms of value-based agreements with Harvard Pilgrim Health Care and "other major health insurers" for Onpattro lipid complex injection, a first-of-its-kind RNA interference therapeutic that was just approved by the FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. "Alnylam is actively discussing VBAs with leading commercial insurers, and has reached agreement in principle on the structure of value-based agreements with Harvard Pilgrim Health Care and other major health insurers, with many ongoing discussions. Based on MMIT, a leading medical policy reporting agency, these engaged payers cover approximately 76 percent of commercial medical lives in the U.S. The goal of these agreements is to ensure that Alnylam is paid based on the ability of Onpattro to deliver outcomes in the real world setting comparable to those demonstrated in clinical trials. Partnering with payers on these agreements is intended to provide more certainty to them for their investment, and help accelerate coverage decisions for patients. The agreements are structured to link Onpattro's performance in real-world use to financial terms," the company stated. "Express Scripts is enthusiastic about this approval as it represents a new therapeutic technology that should improve the lives of patients. We applaud Alnylam for taking a responsible approach to pricing and patient access in the rare disease space, an increasingly complicated challenge. We want to work together toward a common goal of ensuring broad, affordable access to important medicines for rare conditions," said Steve Miller, M.D., Chief Medical Officer, Express Scripts (ESRX).

14:34 EDT Alnylam tells Bloomberg will work with FDA to get broader claims for Onpattro - Alnylam President Barry Greene told Bloomberg that Alnylam can't make heart claims for Onpattro, but will work with the FDA to get broader claims for the drug. He added that the company will release price information for Onpattro on its call scheduled with investors. Alnylam has said it will host a conference call to discuss Onpattro's approval today at 3:00 pm ET.

14:32 EDT Alnylam confirms FDA approves Onpattro to treat polyneuropathy caused by hATTR - Alnylam Pharmaceuticals announced that the United States Food and Drug Administration approved Onpattro lipid complex injection, a first-of-its-kind RNA interference therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated, or hATTR, amyloidosis in adults. "We believe today draws us ever-closer to achieving our Alnylam 2020 goals of becoming a fully integrated, multi-product biopharmaceutical company with a sustainable pipeline. With the potential for the sequential launches of several new medicines in the coming years, we believe we have the opportunity to meaningfully impact the lives of people around the world in need of new approaches to address serious diseases with significant unmet medical needs," said CEO John Maraganore. Onpattro is expected to be available for shipment to healthcare providers in the U.S. within 48 hours. On July 27, patisiran received a positive opinion from the Committee for Medicinal Products for Human Use for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy under accelerated assessment by the European Medicines Agency. The recommended Summary of Product Characteristics for the European Union includes data on secondary and exploratory endpoints. Expected in September, the European Commission will review the CHMP recommendation to make a final decision on marketing authorization, applicable to all 28 EU member states, plus Iceland, Liechtenstein and Norway. Regulatory filings in other markets, including Japan, are planned beginning in mid-2018.

14:10 EDT TherapeuticsMD trading halted, news pending

13:15 EDT Capital World Investors reports 13.2% passive stake in Eros International

13:08 EDT Alnylam's Onpattro approved by FDA to treat polyneuropathy caused by hATTR - The U.S. Food and Drug Administration approved Onpattro infusion for the treatment of peripheral nerve disease, or polyneuropathy, caused by hereditary transthyretin-mediated amyloidosis, or hATTR, in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in peripheral nerves, the heart and other organs, the agency noted. Approval of Onpattro was granted to Alnylam Pharmaceuticals.

13:03 EDT Amicus trading halted, news pending

12:59 EDT FDA approves Alnylam's Onpattro as hATTR treatment

12:31 EDT Consolidated Communications, unions ratify labor pacts in northern NE - Union leaders from the International Brotherhood of Electrical Workers 2320, 2326 and 2327 and the Communication Workers of America Local 1400 informed Consolidated Communications today that union members have ratified the tentative labor agreements reached on Aug. 4. The new contracts, which cover approximately 1,200 workers in Northern New England, will run through Aug. 7, 2021. "We're very pleased our employees ratified these new agreements, which enable us to better serve and support our customers by having increased flexibility to speed the delivery and support of services," said Bob Udell, president and chief executive officer at Consolidated Communications. "The new agreements also enable us to better manage our costs as a sustainable, long-term business." The new contracts go into effect immediately.

12:26 EDT BWS backs hold on Avid Technology following weak Q2 results - Shares of Avid Technology (AVID) declined on Friday after the company reported quarterly results, reiterated its full year guidance, and instituted a new cost savings initiative. WHAT'S NEW: After the close last night, Avid Technology reported a second quarter loss per share of (20c) on revenue of $98.6M, compared to last year's Q2 results of (26c) and $102.37M, respectively. Bookings for the quarter were $110.3M, an increase of 12% year-over-year and 9% sequentially. The company noted that it saw continued strong software revenue growth from subscription and e-commerce sales in the quarter. Looking ahead, Avid reaffirmed and narrowed its FY18 revenue view to $410M-$420M from $404M-$434M. Analysts expect Avid to report FY18 revenue of $409.9M. The company noted that the guidance reflects the adoption of the new revenue recognition standard ASC 606 as of January 1, 2018. With the reaffirmation of its annual guidance, the company said it will not be issuing quarterly guidance for the balance of the year. SAVINGS PLAN: Additionally, Avid CFO Ken Gayron said that the company's leadership team is executing on a new $20M non-personnel-related savings plan that he expects will "directly improve" the company's EBITDA and free cash flow. STREET RESEARCH: After the report, BWS Financial analyst Hamed Khorsand maintained a Hold rating and $5 price target on the stock, saying that the quarter marked the second straight quarter where Avid experienced an issue in the business for "not fully achieving their goals in the quarter." The analyst noted that the stock could end up trading near the $5 level for another three months until the firm reports Q3 results. Investors would be "well served" to watch from the sideline until there is some "tangible" improvement in revenue and free cash flow, Khorsand contends in the note. PRICE ACTION: In afternoon trading, shares of Avid Technology are off earlier lows, but are still down 3.2% to $5.40.

12:21 EDT Alnylam trading halted, news pending

12:00 EDT Turkcell falls -13.3% - Turkcell is down -13.3%, or -75c to $4.91.

12:00 EDT Veritiv rises 16.9% - Veritiv is up 16.9%, or $6.65 to $46.00.

12:00 EDT Medley Management rises 44.3% - Medley Management is up 44.3%, or $1.55 to $5.05.

11:37 EDT Cohen & Steers reports 10.93% passive stake in Retail Value

11:04 EDT GATX reports Ellman to replace Lyons as CFO - GATX Corporation announced a series of senior leadership changes, effective immediately. Robert Lyons will become Executive Vice President and President, Rail North America. Lyons has most recently served as Executive Vice President and Chief Financial Officer. Thomas Ellman will become Executive Vice President and CFO. Ellman has most recently served as Executive Vice President and President, Rail North America. Paul Titterton will become Senior Vice President and Chief Operating Officer, Rail North America, responsible for Rail North America's Operations and Fleet Organizations. Michael Brooks will become Senior Vice President, Portfolio Management. Amita Shetty will become Senior Vice President, Business Development. Robert Zmudka will become Senior Vice President and Chief Commercial Officer Rail North America. Chairman and CEO Brian Kenney stated, "I am fortunate to work with an extremely capable senior leadership team at GATX, and I believe the changes we are implementing will continue to drive the excellent performance that our shareholders expect. The changes should also enhance our growth efforts, further develop our leaders, and assist the GATX Board of Directors in their ongoing succession planning efforts."

10:32 EDT Lockheed Martin, Sweden sign agreement for Hit-to-Kill PAC-3 MSE Missiles - U.S. and Sweden officials formalized an agreement for Sweden to purchase Lockheed Martin's Patriot Advanced Capability-3 Missile Segment Enhancement missiles and related support equipment. Once the contract is signed, Sweden will become the sixth international customer to sign an agreement to procure PAC-3 MSE. Sweden joins the U.S., Qatar, Japan, Romania, Poland and the United Arab Emirates to procure PAC-3 MSE. Several other nations have also expressed an interest in enhancing their missile defense capabilities with the PAC-3 MSE as part of the Patriot system. Lockheed Martin is the prime contractor on the PAC-3 MSE upgrade to the Patriot air defense system. The upgraded PAC-3 MSE expands the lethal battlespace with a dual-pulse solid rocket motor, providing increased performance in altitude and range. PAC-3 MSE is a high-velocity interceptor that defends against incoming threats, including tactical ballistic missiles, cruise missiles and aircraft. The missile uses Hit-to-Kill technology, which engages threats through kinetic energy via body-to-body contact.

10:30 EDT Digital Turbine 'very near finalizing' renewal with 'leading U.S.-based carrier' - Along with the company's announcement last night of financial results for the fiscal first quarter, Digital Turbine (APPS) CEO Bill Stone stated: "Demand for our rapidly evolving suite of product solutions from existing and prospective new partners and advertisers is at all-time highs. We are very near finalizing a renewal of our valued partnership with a leading U.S.-based carrier. We view this renewal as an endorsement of our expanded platform and product roadmap, and it is expected to provide a source of meaningful potential growth for the company in the years ahead. Additionally, I continue to be optimistic about the company's capacity to partner with leading global OEMs as a means of significantly expanding the platform's reach, especially as it relates to the penetration and monetization of global markets where the 'unlocked' BYOD model prevails." Though not named, analyst have identified the U.S. carrier as Verizon (VZ). In early trading, Digital Turbine shares are up 3c, or 2%, to $1.47.

10:00 EDT BBVA Banco Frances falls -11.1% - BBVA Banco Frances is down -11.1%, or -$1.36 to $10.85.

10:00 EDT Pretium Resources rises 16.2% - Pretium Resources is up 16.2%, or $1.25 to $9.02.

10:00 EDT Medley Management rises 41.5% - Medley Management is up 41.5%, or $1.45 to $4.95.

09:50 EDT The Intersection: Crypto and Wall Street This Week - As bitcoin, ethereum and other cryptocurrencies get increasing attention from investors, Wall Street and its traditional banks continue to adjust to the shift. Catch up on this week's top stories highlighting the intersection of these old guard and new school areas of finance with this recap compiled by The Fly. 1. SEC DELAYS DECISION ON CRYPTO ETF: Bitcoin fell on Wednesday after the U.S. Securities and Exchange Commission postponed a decision on a proposed bitcoin exchange-traded fund, CNBC reported. Investment firm VanEck partnered with Solid X in an effort to launch an ETF backed by actual bitcoins rather than futures in VanEck's third attempt to push the ETF through after being rejected by the SEC twice previously. The SEC said it is postponing its decision until September 30. 2. GOLDMAN CONSIDERS CRYPTO CUSTODY OFFERING: Goldman Sachs (GS) is mulling a plan to offer custody for cryptocurrency funds, meaning the bank would hold the digit assets on behalf of the funds, reducing risk for clients looking to protect against the threat of losing investments to rogue attacks, Bloomberg reported Monday. Deliberations are ongoing and no timeline has been established for when the firm will roll out the services. 3. COINBASE ANNOUNCES HIGHER CRYPTO TRADING LIMITS: Coinbase said in a blog post on Tuesday: "Today we're announcing immediate trading and significantly higher default limits for Coinbase accounts...With this update, customers will receive an immediate credit for the funds being sent from their bank account. They can then buy and sell crypto to and from their USD wallet right away, but cannot send their funds off the Coinbase platform until the funds coming from their bank have settled. We are also increasing limits for the majority of our US customers. Until now, the maximum allowable purchase was $25,000 weekly. For verified customers, the limit will now be $25,000 daily, a 7x increase over our prior limits. And once your funds are transferred to Coinbase, there are no longer any limits to how much you can buy or sell at a time." 4. GSR CAPITAL TO INVEST IN TZERO: Overstock.com (OSTK) and t0.com announced Thursday that the companies have both signed term sheets with GSR Capital to invest up to $374.55M in exchange for common equity in blockchain subsidiary tZERO and common equity in Overstock.com. GSR Capital has also agreed to purchase $30M in tZERO Security Tokens. 5. SSC RAISES $12M: Seven Stars Cloud Group (SSC) announced Friday that it has raised $12M from Advantech Capital Investment II and restructured its Private Placement from GT Dollar to $10M. The company will use these investments to accelerate the adoption of its artificial intelligence and blockchain-based technologies into various business verticals. Advantech has subscribed to $12M via a Convertible Note with SSC. CRYPTO STOCK PLAYS: Cryptocurrency revenues have been pointed to as reasons to be bullish on Advanced Micro Devices (AMD) and Nvidia (NVDA) in select research. Overstock, DPW Holdings (DPW), Kodak (KODK), Seven Stars Cloud, Riot Blockchain (RIOT), Pareteum (TEUM) and Social Reality (SRAX) are other stocks that have been touted, or promoted themselves, as a way to play the crypto theme. PRICE ACTION: As of time of writing, bitcoin dropped about 13.1% this week to $6,492 in U.S. dollars, according to CoinDesk. WANT BITCOIN NEWS ALERTS?: To receive alerts on stories relating to bitcoin and other cryptocurrencies, Fly subscribers can enter "Bitcoin" into the "Add symbols" box of their portfolios.

09:47 EDT Intrexon falls -10.0% - Intrexon is down -10.0%, or -$1.54 to $13.85.

09:47 EDT Turkcell falls -17.5% - Turkcell is down -17.5%, or -99c to $4.67.

09:47 EDT Pretium Resources rises 9.7% - Pretium Resources is up 9.7%, or 75c to $8.51.

09:27 EDT Caesars increases share repurchase authorization to $750 M - Caesars has increased its share repurchase authorization to $750M of the company's outstanding common stock. Since the initial $500M repurchase authorization on May 2, the company has acquired 23 million shares of its common stock, approximately 3.3% of the company's outstanding shares. The purchases were made at an average price of $10.22 per share for a total of $232M. With the increase in authorization, the company has $518M remaining under its repurchase program.

09:01 EDT John Bean Technologies authorizes $30M share repurchase program - JBT authorized a new share repurchase plan of up to $30M of the company's common stock, effective January 1, 2019 through December 31, 2021.

09:01 EDT Yum! Brands announces $2B additional share repurchase authorization

08:35 EDT Seven Stars Cloud Group raises $12M from Advantech Capital II - Seven Stars Cloud Group has successfully raised $12M from Advantech Capital Investment II and restructured its Private Placement from GT Dollar to $10M. The company will use these investments to accelerate the adoption of its artificial intelligence and blockchain-based technologies into various business verticals. Advantech Capital is a private equity fund focused primarily on high-growth and innovation-driven industry sectors. Advantech has subscribed to $12M via a Convertible Note with SSC.

08:32 EDT T. Rowe Price reports preliminary AUM $1.07T as of July 31 - T. Rowe Price reported preliminary month-end assets under management of $1.07 trillion as of July 31. Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $0.5B in July and $14.1B for the year-to-date period ended July 31.

08:17 EDT Brookdale Senior Living names Steven Swain as CFO - Brookdale Senior Living appointed Steven Swain as its Executive VP and CFO. Swain will have responsibility for the company's finance, financial planning and analysis, investor relations, market insights and analytics, tax and treasury functions. He is expected to start on September 4 and will replace the company's current Interim CFO, Teresa Sparks. Swain most recently served as CFO of DISH Network since October 2014 and previously serving in roles of increasing responsibility within the company since 2011.

08:04 EDT Sprint offers iPhone X for $5/month - Sprint is "flashing" another amazing deal. Starting August 10, new and existing customers who add a new line of service and trade in an eligible device can get the unrivaled iPhone X for $5 a month with Sprint Flex lease. The promotion is only available for one week at Sprint stores.

08:02 EDT Legg Mason reports preliminary AUM approximately $749.2B as of July 31 - This month's AUM included net long-term outflows of $3B, driven by net outflows in fixed income of $1.9B, alternatives of $0.6B, and equity of $0.5B.

08:01 EDT Manning & Napier reports preliminary AUM $23B as of July 31 - Compared with $22.8B at June 30, 2018.

07:32 EDT Axon says Charlotte Fire Department to deploy Evidence.com - Axon announced that Charlotte Fire Department will deploy Axon's digital evidence management solution, Evidence.com, making it the first major city fire department to join the Axon network. The department's arson unit will be the first to deploy Evidence.com services as part of a larger proof of concept. This order was received in the second quarter of 2018.

07:04 EDT General Finance subsidiary Pac-Van acquires assets from Delmarva Trailer Sales - General Finance subsidiary Pac-Van acquired the assets of Delmarva Trailer Sales and Rentals of Elkridge, Maryland on Thursday, August 9th. Delmarva Trailer Sales and Rentals provides its customers with portable storage containers, office containers, portable storage trailers and office trailers. This acquisition adds a location in Maryland, over 500 additional rental units in the fleet and three new professionals.

07:02 EDT Peak Rock Capital affiliate to acquire TNT Crust from Tyson Foods - An affiliate of Peak Rock Capital announced that it has signed a definitive agreement to acquire the TNT Crust business from Tyson Foods. Founded in 1981, TNT is a leading manufacturer and distributor of partially baked, self-rising, flat breads and other pizza crusts for the foodservice and retail channels. TNT has a diverse customer base, including blue chip national and regional restaurants, pizza manufacturers, and foodservice distributors. Headquartered in Green Bay, Wisconsin and operating out of two BRC-certified manufacturing facilities, the Company has built an excellent reputation in the industry for its outstanding product quality, innovative product solutions and unmatched customer service. The parties expect the transaction, which is subject to customary closing conditions, to close in September 2018.

06:12 EDT Aralez enters two purchase agreements worth $250M to sell almost all assets - Aralez announced that it intends to enter into purchase agreements with two separate stalking-horse purchasers to sell its main operating businesses: an agreement to sell its Vimovo royalties and Canadian operations to Nuvo Pharmaceuticals in a transaction valued at $110M and an agreement to sell its Toprol-XL franchise to its secured lender, certain funds managed by Deerfield Management, in a transaction valued at $140M. The company is also engaged in ongoing efforts to sell the assets not being sold in either of the proposed transactions and intends to wind down its operations following the consummation of the sales. The letters of intent signed with each of Nuvo and the company's secured lender included the material terms of each of the proposed transactions. Each proposed transaction is subject to entry into mutually agreeable definitive agreements, and in the case of Nuvo, obtaining committed financing, which is expected to be provided by the company's secured lender. Aralez has agreed to negotiate exclusively with Nuvo until August 19. Closing of each proposed transaction is subject to the receipt of applicable regulatory approvals and the satisfaction or waiver of other customary closing conditions. The proposed transactions are not conditioned on one another and will be subject to approval by the applicable courts supervising the restructuring proceedings described below. Aralez, together with its subsidiaries, intends to seek and obtain customary relief from the courts to permit it to continue to operate its business in the ordinary course without interruption during the sale process. In addition, Aralez has obtained commitments for debtor-in-possession, or DIP, financing of approximately $15M, from its secured lender, which is subject to approval of the courts. The company intends to use the proceeds from the DIP financing, in addition to cash flow from operations, to pay for all goods and services from vendors provided after the CCAA and Chapter 11 filing date in accordance with their current terms. In addition, the company and its subsidiaries have filed a number of customary pleadings seeking authorization from the courts to pay certain pre-petition obligations, support their business operations and transition them through the restructuring proceedings and the sale process. These include the payment of employee wages, salaries and benefits, and certain obligations to vendors. The sales and restructuring proceedings are the culmination of a previously announced financial and strategic review undertaken by the board of directors of the company. While the company continued to address and improve its financial profile through several cost savings initiatives, corporate restructurings and the payment In kind deferral of its July 1 interest payment until August 15, it became increasingly apparent during the course of the board's financial and strategic review, that absent the legal protection afforded through the restructuring proceedings, the company's cash position would continue to deteriorate. Following completion of the board's strategic review, after careful consideration of all available alternatives and having given due consideration to the interests of all stakeholders, the boards of directors of the company and each of its North American and Irish subsidiaries, with the assistance, input and advice from legal and financial advisors, have unanimously determined that a sale process under court supervision is in the best interests of the companies. Rob Harris, a director of the company, abstained from voting on these matters due to a potential conflict of interest relating to the ongoing sale process. In connection with the filing and to facilitate the administration of the restructuring proceedings more efficiently, the size of the board has been reduced to four members.

06:09 EDT Altaba announces final results of tender offer - Altaba announced final results of its tender offer to purchase up to 195M - approximately 24% - shares of its common stock, at a price per share equal to 35 ADSs of Alibaba Group Holding, a Cayman Islands company, which are held by the Fund in its investment portfolio, less any Alibaba ADSs withheld to satisfy applicable withholding taxes and subject to adjustment for fractional Alibaba ADSs, and $8.93 in cash, less any cash withheld to satisfy applicable withholding taxes and without interest. A total of 358,184,048 shares of the Fund's common stock were properly tendered and not properly withdrawn, and the tender offer was oversubscribed. The proration factor for the tender offer is approximately 54.42%. The aggregate purchase price for the shares purchased by the Fund in the tender offer is approximately 68,250,000 Alibaba ADSs and $1,741,350,000 in cash. The value per share of the offer consideration on such date was $71.06, which represented approximately 92.04% of Altaba's current estimated NAV per share and approximately 74.31% of Altaba's most recently published NAV per share. The Fund sold approximately 32M Alibaba ADSs at an average price of $178.91 per Alibaba ADS

06:03 EDT Gemphire Therapeutics announces termination of Phase 2a trial of gemcabene - Gemphire Therapeutics announces that the Data and Safety Monitoring Board at Emory University School of Medicine overseeing the investigator-led open label Phase 2a proof-of-concept trial evaluating gemcabene in pediatric patients with non-alcoholic fatty liver disease has recommended that the trial be terminated due to unanticipated problems. This pediatric NAFLD trial was initiated in early 2018. Patients were treated with gemcabene at a dose of 300 mg once daily. The primary endpoint is a measure of the change in serum alanine transaminase, an enzyme that serves as a biomarker of liver function, from baseline to 12 weeks, and secondary endpoints include, among others, change in hepatic steatosis (liver fat) as measured by non-invasive magnetic resonance imaging - proton density fat fraction. Data on the first three patients who underwent 12 weeks of treatment showed that all three experienced an increase in liver fat content, as measured by MRI-PDFF, and demonstrated increases in ALT. The increase in liver fat was deemed an unexpected problem by the trial investigator because it was an unexpected consistent pattern of worsening of the disease, rather than improvement, creating risk to the patients, which the investigator believed was likely due to the drug. Other patients currently enrolled in the trial have now been taken off gemcabene and early termination visits are being scheduled. The DSMB has recommended additional follow-up of the study subjects to gather additional safety data. The DSMB will provide Gemphire with a written report of their findings in the future once all the patient results have been collated and analyzed.

05:08 EDT Lydall to acquire Interface Performance Materials for $265M in cash - Lydall announced it has entered into an agreement to acquire Interface Performance Materials for $265M in cash. The transaction will further advance Lydall's engineered materials offering in new markets with similar technologies utilized in our Performance Materials business. Interface is a leading globally-recognized brand that delivers complete sealing solutions with a comprehensive product portfolio, deep in-house technical capabilities and vertical integration. The transaction is expected to close in Q3, subject to the completion of specified closing conditions, including receipt of customary merger control approval from U.S. authorities. Interface's reported sales and adjusted EBITDA for the fiscal year ended December 31, 2017 were $142 million and $26 million, respectively. The business is expected to achieve sales of approximately $150 million and adjusted EBITDA of approximately $29 million in the trailing 12 months ending August 31, 2018. Lydall expects to leverage its business efficiencies, operating discipline and economies of scale to generate an estimated annual cost savings of approximately $4 million by 2020. The acquisition is expected to be accretive to Lydall's earnings, net of the effects of purchase accounting approximately six months after closing. Lydall's financial results for the Second Quarter 2018 included approximately $1.1 million of expenses related to this transaction, and it is estimated that approximately $3 million of additional non-recurring transaction and integration expenses will be incurred over the second half of 2018 and approximately $1 million in 2019. The Interface business will become part of the Performance Materials operating segment with the expectation to complete integration within one year of closing. The transaction is expected to be financed predominantly from borrowings under the company's amended credit facility; the provisions of which are being finalized with our banking partners.